Overview
Observational Study of Pharmacological Treatment for Premature Ejaculation Concurrent With Erectile Dysfunction
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2021-04-01
2021-04-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
Premature ejaculation (PE) is a common disease in the andrology clinic. Currently, the effectiveness and outcome differences of drug treatment still need to be studied and demonstrated. Premature ejaculation concurrent with erectile dysfunction (ED) is common in outpatient clinics. The preferred treatment plan for these patients still needs to be further studied and explored, and the difference in the efficacy of different treatment regiments remain to be evaluated.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Yan-Ping HuangTreatments:
Tadalafil
Criteria
Inclusion Criteria:1. PE concurrent with ED: the IELT is less than 3 minutes, the PEDT score is ≥11 points,
and 5≤IIEF-5≤21 points.
2. 18-60 years old, outpatient or physical examination population, with regular sex
partners and regular sex life;
3. Having the data below,and willing to participate in the trial(1)Demographic
information: age, gender, nationality, birthplace, etc;(2) Physical examination data:
height, weight, abdominal circumference, blood pressure, heart rate, etc ;(3) Medical
history data: history of present illness, past medical history, family history,
etc;(4) Scale evaluation: Premature Ejaculation Diagnostic Tool (PEDT), Premature
Ejaculation Profile (PEP), International Erectile Function Score-5(IIEF-5), Erectile
Hardness Grading Score (EHGS), Clinical Global Impression of Change (GICC);
Exclusion Criteria:
1. Age <18 years or> 60 years;
2. There is a history of acute and chronic diseases, major trauma and surgery, etc;
3. A long history of medication;
4. There is a history of unstable myocardial infarction and cerebral infarction;
5. A history of cardiogenic shock, severe heart failure, severe ventricular arrhythmia,
etc;
6. There are serious diseases such as malignant tumors, chronic liver and kidney
diseases, etc.